What the current evidence can establish
Human safety data for BPC-157 is too limited and formulation-specific to establish reliable incidence rates for systemic research-product use.
- A small or route-specific study cannot characterize uncommon or long-term adverse effects.
- Absence of reported events is not proof that a compound or product is safe.
- Research-vendor identity, purity, sterility, endotoxin, and stability remain separate risks.
What this evidence review covers
State what little is known about BPC-157 safety and foreground uncertainty.
- Human observations and sample-size limit
- Preclinical evidence is not a safety database
- FDA immunogenicity/impurity/characterization concerns
- Product-quality risks
- Unknown long-term and route-specific effects
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
direct human evidence with explicit uncertainty
No reported effects in two participants cannot establish general safety or rule out uncommon harms.
regulatory
FDA flags limited safety information and potential immunogenicity/impurity concerns.
| Evidence class | What the source supports |
|---|---|
| direct human evidence with explicit uncertainty | No reported effects in two participants cannot establish general safety or rule out uncommon harms. |
| regulatory | FDA flags limited safety information and potential immunogenicity/impurity concerns. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Evidence class: primary uncontrolled human pilot. What it supports: Two previously exposed adults; short-term vital-sign and laboratory observations; no efficacy endpoint.
What it does not establish: General safety, any efficacy claim, a dosage schedule, a monitoring protocol, or other routes.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
BPC-157 and Src-Caveolin-1-eNOS signaling in experimental tissue repair
Evidence class: primary preclinical. What it supports: Mechanistic hypotheses in experimental models.
What it does not establish: Human healing, recovery timelines, or treatment benefit.
Questions this page answers
Does BPC-157 have no side effects?
That claim is unsupported. The human sample is far too small to define a profile.
Are animal studies enough to establish safety?
No. They do not replace controlled human safety data.
What remains unresolved
- No adequate human safety database.
- No route-specific long-term evidence.
- No verified adverse-event ledger for vendor products.